publication venue for
- Overview of the global vaccine ecosystem. 22:749-763. 2023
- Evaluating the relationship between myocarditis and mRNA vaccination. 21:83-89. 2022
- Determining optimal community protection strategies for the influenza vaccine. 18:755-764. 2019
- Human type 5 adenovirus-based tuberculosis vaccine: is the respiratory route of delivery the future?. 13:927-930. 2014
- Type I interferon regulation of natural killer cell function in primary and secondary infections. 12:875-884. 2013
- A novel genetically engineeredMycobacterium smegmatis-based vaccine promotes anti-TB immunity. 11:35-38. 2012
- Optimizing vaccine-induced CD8+T-cell immunity: focus on recombinant adenovirus vectors. 10:1307-1319. 2011
- Effective control of viral infections by the adaptive immune system requires assistance from innate immunity. 9:1143-1147. 2010
- Importance of T-cell location rekindled: implication for tuberculosis vaccination strategies. 8:1465-1468. 2009
- Heterologous boost vaccines for bacillus Calmette-Guerin prime immunization against tuberculosis (vol 6, pg 539, 2007). 7:274-274. 2008
- Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.. 6:539-546. 2007
- Heterologous boost vaccines for bacillus Calmette–Guérin prime immunization against tuberculosis. 6:539-546. 2007
- T-cell immunity generated by recombinant adenovirus vaccines. 6:347-356. 2007
- Peptide-based immunotherapy: a novel strategy for allergic disease. 4:881-889. 2005
- Tuberculosis vaccines: the past, present and future. 1:341-354. 2002